Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1141-1160 of 3,900 trials

MECP2 Duplication Syndrome: ION440 Treatment Study

We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.

MECP2 Duplication SyndromeSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematology

Plaque Psoriasis: ESK-001 Treatment Study

We are testing a new medication, ESK-001, for people with moderate to severe plaque psoriasis. The study aims to see if it works better than a placebo and an existing treatment.

Moderate to Severe Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Investigational Drug MP-101 for ALS and Alzheimer's Disease

We are studying how MP-101 affects laboratory signs of ALS and Alzheimer's in patients. This research aims to gather insights on its potential impact on these diseases.

Amyotrophic Lateral Sclerosis (ALS)Alzheimer’s Disease (AD)Safety phase (I)Neurology

MOGAD: Evaluating Satralizumab Treatment

We are studying the effectiveness and safety of satralizumab for patients with MOGAD. This trial compares the new treatment to a placebo to see how well it prevents disease relapses.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Genitourinary Syndrome of Menopause: Cellular Matrix Treatment

We are studying a new treatment combining platelet-rich plasma and hyaluronic acid for women with genitourinary syndrome of menopause. This trial compares its effects to a standard estrogen gel to see which works better for symptom relief.

Genitourinary Syndrome of Menopause3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and Obstetrics

Atrial Fibrillation: Amiodarone Treatment Study

We are studying whether a longer or shorter course of amiodarone helps people with persistent atrial fibrillation return to a normal heart rhythm before a procedure. This may improve outcomes for patients undergoing electrical cardioversion.

Atrial Fibrillation1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCardiology

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

B-Cell Aggressive Lymphoma: ARI0003 Cell Infusion

We are testing a new cell infusion treatment for patients with relapsed or refractory aggressive B-cell lymphoma. This study aims to see how well ARI0003 cells work in helping these patients.

Aggressive B-cell LymphomaSafety phase (I)Oncology

Ruxolitinib Rollover Study for Cancer Patients

We are providing continued access to ruxolitinib for patients who have previously participated in related studies. The goal is to evaluate the safety of ruxolitinib alone or with other cancer treatments.

MyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Cervical Cancer: Fertility-Sparing Treatment Study

We are studying a new approach for women with early-stage cervical cancer to see if chemotherapy followed by surgery can help preserve fertility. This trial aims to evaluate the safety and effectiveness of this treatment method.

Cervical Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Severe Hyponatremia: DDAVP Treatment Study

We are investigating whether DDAVP can help prevent sodium overcorrection in patients with severe hyponatremia. This study aims to improve safety and outcomes for those experiencing dangerously low sodium levels.

Low Sodium Levels (Hyponatremia)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Ulcerative Colitis: Adalimumab Treatment Comparison

We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.

Ulcerative Colitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pneumonia Prevention: 20-Valent Pneumococcal Vaccine

We are studying whether a new 20-valent pneumococcal vaccine helps prevent pneumonia in adults aged 65 and older. This trial will assess its effectiveness against specific types of pneumonia caused by certain bacteria.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Breast Cancer: Trastuzumab and Pertuzumab Study

We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.

HER2-positive Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Dupuytren's Contracture: Bacterial Collagenase Treatment

We are studying a new bacterial collagenase injection for patients with Dupuytren's contracture to see if it improves hand function and reduces contracture compared to a placebo.

Dupuytren's Contracture6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology